A new Phase 2 clinical trial (ClinicalTrials.gov Identifier: NCT01938495) titled “Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)” is examining the efficacy of DPS compared to standard of care in patients with ALS,…
Dr. Jonathan Kipnis, Ph.D., professor of neuroscience and Director of the Center for Brain Immunology and Glia (BIG) at the University of Virginia Medical School, and his research team from the Laboratory of Cellular and Molecular Neuroimmunology, made an important discovery in the field…
Biopharmaceutical company MediciNova, Inc. announced that an abstract on the company’s ongoing clinical trial of MN-166 (ibudilast) to address amyotrophic lateral sclerosis (ALS) has been accepted for presentation at the American Academy of Neurology (AAN) 67th Annual Meeting, which will take place on…
On February 23rd, the office of the Congressionally Directed Medical Research Programs (CDMRP) released a pre-announcement through the Department of Defense Amyotrophic Lateral Sclerosis Research Program (ALSRP) for the opening of the FY15 appropriations grant application cycle. This pre-announcement is meant to give investigators the opportunity to begin preparations for submitting…
Now in its second year as a Gold-level national partner, BAYADA Home Health Care will be supporting several initiatives by The ALS Association, including Walk to Defeat ALS to raise funds from events all across the nation in the fight against amyotrophic lateral sclerosis (ALS).
A research team led by Diego Minciacchi of the University of Florence in Italy identified a population of neurons that might explain the cognitive alterations antecedent to motor symptoms in Amyotrophic Lateral Sclerosis (ALS). The study entitled, “Increased anxiety-like behavior and selective learning impairments are concomitant to…
A study at King’s College London with patients recruited from the South-East ALS Register in England concluded that decision-making processes for ALS patients are complex, multidimensional and need individualized treatment and more patient-focused support. The results were presented in a publication entitled: “Accepting or…
Biopharmaceutical company MediciNova, Inc. recently completed enrollment of the first 30 patients with amyotrophic lateral sclerosis (ALS) for its clinical trial to evaluate the efficacy MN-166 (ibudilast). The company plans to add another 30 participants…
In a new study entitled “Neuronal death induced by misfiled prion protein is due to NAD+ depletion and can be relieved in vitro and in vivo by NAD+ replenishment,” researchers report that in protein misfolding neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis, neuronal death…
In a new study entitled “Transcriptome profiling of expression changes during neuronal death by RNA-Seq,” a research team employed RNA-sequencing to identify novel genes that might help regulate the death of neurons, a characteristic of neurodegenerative diseases. The study was published in the journal…
Get regular updates to your inbox.
